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A vast array of instruments are available for measuring
disease activity in juvenile idiopathic arthritis (JIA). How-
ever, due to the high variability in the clinical presentation
and course of JIA, no single measure can reliably capture
disease activity in all patients. On the other hand, assess-
ment of all measures individually may cause methodologi-
cal and statistical problems, especially when these
measures are employed as endpoints in clinical trials. Sev-
eral approaches can be followed to achieve a more rational
and standardized evaluation. One of these approaches is
based on the so-called composite disease activity scores,
which are made of a pool of individual measures and are
aimed to quantify the absolute level of disease activity by
providing one summary number on a continuous scale.
Recently, the first composite disease activity score for JIA,
named Juvenile Arthritis Disease Activity Score (JADAS),
has been developed. In validation analyses, it was found to
have good metrologic properties, including the ability to
predict the disease outcome. The cutoff values of the
JADAS that corresponded with the states of inactive dis-
ease and minimal disease activity, or reflected the physi-
cian’s, parent’s or child’s subjective rating of remission or
the parent’s or child’s satisfaction with the outcome of the
illness were established recently. These cutoffs represent
an additional clinical tool that, if applied regularly in daily
practice, may allow tighter control of therapy, support the
optimization of treatment on an individual patient basis,
and help prevent the development of joint damage and
physical disability. JIA is characterized by prolonged syno-
vial inflammation that may cause irreversible alterations in
joint structures. Permanent changes may also occur in
extra-articular organs/systems, such as the eye (as a com-
plication of chronic anterior uveitis), or may result from
side effects of medications. The Juvenile Arthritis Damage
Index (JADI) was devised to enable a thorough detection
of articular and extra-articular damage in children with
JIA. The JADI is aimed to capture damage, defined as per-
sistent changes in anatomy, physiology, pathology or func-
tion, which may be the consequence of previous active
disease, side effects of therapy, or co-morbid conditions, is
not due to currently active arthritis, and is present for at
least 6 months. Damage is often irreversible and cumula-
tive and, thus, damage scores are most frequently expected
to increase or remain stable over time. However, because
some forms of damage may improve or even resolve in
growing children, in some cases scores may decrease. The
index is composed of two parts, one devoted to the assess-
ment of articular damage (JADI-A) and one devoted to
the assessment of extraarticular damage (JADI-E). In vali-
dation analyses, the JADI was found to be feasible and to
possess both face and content validity; furthermore, it
exhibited good convergent construct validity, excellent
reliability (interrater agreement and internal consistency),
and strong discriminative validity in a large cohort of JIA
patients with long-standing disease.
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